These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36781879)

  • 21. Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA.
    Liu Y; Dai L; Feng X; Gao R; Zhang N; Wang B; Han J; Zou Q; Guo X; Zhu H; Liu J; Qin C; Zhang Y; Bao L; Li M
    Mol Biomed; 2021; 2(1):29. PubMed ID: 34766005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle.
    Royal JM; Simpson CA; McCormick AA; Phillips A; Hume S; Morton J; Shepherd J; Oh Y; Swope K; DeBeauchamp JL; Webby RJ; Cross RW; Borisevich V; Geisbert TW; Demarco JK; Bratcher B; Haydon H; Pogue GP
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
    Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice.
    Maltseva M; Galipeau Y; Renner TM; Deschatelets L; Durocher Y; Akache B; Langlois MA
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination.
    Castro EF; Acosta J; Moriena L; Rios Medrano M; Tejerina Cibello M; Codino E; Taborda MÁ; Álvarez DE; Cavatorta AL
    mSphere; 2023 Jun; 8(3):e0066222. PubMed ID: 37070983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern.
    Renner TM; Akache B; Stuible M; Rohani N; Cepero-Donates Y; Deschatelets L; Dudani R; Harrison BA; Baardsnes J; Koyuturk I; Hill JJ; Hemraz UD; Régnier S; Lenferink AEG; Durocher Y; McCluskie MJ
    Front Immunol; 2023; 14():1182556. PubMed ID: 37122746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.
    Capone S; Fusco FM; Milleri S; Borrè S; Carbonara S; Lo Caputo S; Leone S; Gori G; Maggi P; Cascio A; Lichtner M; Cauda R; Dal Zoppo S; Cossu MV; Gori A; Roda S; Confalonieri P; Bonora S; Missale G; Codeluppi M; Mezzaroma I; Capici S; Pontali E; Libanore M; Diani A; Lanini S; Battella S; Contino AM; Piano Mortari E; Genova F; Parente G; Dragonetti R; Colloca S; Visani L; Iannacone C; Carsetti R; Folgori A; Camerini R;
    Cell Rep Med; 2023 Jun; 4(6):101084. PubMed ID: 37315558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
    O'Kennedy MM; Abolnik C; Smith T; Motlou T; Goosen K; Sepotokele KM; Roth R; du Preez I; Truyts A; Stark HC; Magwaza M; Mahanjana O; Verschoor JA; Moore PL; Lemmer Y
    Vaccine; 2023 Mar; 41(13):2261-2269. PubMed ID: 36868876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses.
    Eldi P; Cooper TH; Prow NA; Liu L; Heinemann GK; Zhang VJ; Trinidad AD; Guzman-Genuino RM; Wulff P; Hobbs LM; Diener KR; Hayball JD
    Immunol Cell Biol; 2022 Apr; 100(4):250-266. PubMed ID: 35188985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates.
    Pavot V; Berry C; Kishko M; Anosova NG; Li L; Tibbitts T; Huang D; Raillard A; Gautheron S; Gutzeit C; Koutsoukos M; Chicz RM; Lecouturier V
    Nat Commun; 2023 Mar; 14(1):1309. PubMed ID: 36894558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions.
    Kaplonek P; Cizmeci D; Fischinger S; Collier AR; Suscovich T; Linde C; Broge T; Mann C; Amanat F; Dayal D; Rhee J; de St Aubin M; Nilles EJ; Musk ER; Menon AS; Saphire EO; Krammer F; Lauffenburger DA; Barouch DH; Alter G
    Sci Transl Med; 2022 May; 14(645):eabm2311. PubMed ID: 35348368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates.
    Pavot V; Berry C; Kishko M; Anosova NG; Huang D; Tibbitts T; Raillard A; Gautheron S; Gutzeit C; Koutsoukos M; Chicz RM; Lecouturier V
    Nat Commun; 2022 Mar; 13(1):1699. PubMed ID: 35361754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
    Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
    Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines.
    Maharjan PM; Choe S
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.